Skip to main content

LabCorp to Buy CRO Tandem Labs

NEW YORK (GenomeWeb News) – Laboratory Corporation of America will buy the pharmaceutical and biotechnology contract research services company Tandem Labs for an undisclosed sum, LabCorp said today.
 
Under the agreement, Burlington, NC-based LabCorp will buy all of the outstanding shares of Tandem Labs and its parent company, Northwest Toxicology. Tandem will retain its name and management structure and will operate as part of LabCorp’s Esoterix clinical trials group.
 
Tandem offers discovery, preclinical, and clinical drug development services and has around 54,000 square feet of lab space and over 30 LC/MS/MS instruments spread among its branches in Utah, New Jersey, and Massachusetts.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.